April 27, 2022
Webinar
On behalf of the organizing committee, we cordially invite all of the leading scientists, academicians, researchers, Business delegates, exhibitors, sponsors and students from all over the world to attend the 14th International Conference on Dementia and Dementia Care on April 24, 2022 held as Webinar.
Dementia care 2022 has been thoughtfully planned to meet the expectations of our attendees and thus shares an insight into the recent research and cutting edge technologies, which gains immense interest and provides ideal setting for an interactive gathering of information.
Our aim is to explain the untouched science behind the mystery of Dementia, their mechanism, diagnosis, treatment and management as well as to engage in a lively discussion on current breakthroughs in the field of dementia.
It’s time to raise awareness about the importance of Dementia in our day to day life throughout the globe.
We welcome all the experienced & aspiring researchers in the field of Dementia & Dementia Care from across the world to share their rich experience & knowledge with our attendees at the most anticipated Dementia Care 2022 Conference.
Theme: “Dementia A Growing and Serious Psychological Issue”.
Dementia Care 2022 will feature a variety of educational events such as keynote sessions, plenary speeches, workshops, and poster presentations, all of which will be judged and rewarded by members of the Editorial Board.
Who can attend Dementia Care 2022?
Session 1: Dementia and Aging
Dementia is a term used for the loss of the ability to remember, think, or make decisions that interfere with doing daily tasks. Dementia and age-related memory decline can be distinguished in numerous ways. Dementia is not a normal part of ageing, even though it usually affects older adults. Many older adults live their entire lives without ever experiencing dementia.
Session 2: Lewy Body Dementia
Depositions of the protein alpha-synuclein in neurons cause Lewy body dementia. Hallucinations and rigidity in the movement are symptoms of Lewy body dementia. Disruption of brain cells occurs in Lewy body dementia, and the diagnosis of Lewy body dementia is only possible after a year of observation and progression of symptoms with Parkinson's disease. If cognitive problems emerge within a year of movement abnormalities doctors declare it as Lewy body Dementia; if not, then it is declared as Parkinson’s disease.
Session 3: Vascular Dementia
Vascular dementia is caused by a disruption in the brain's blood supply. It usually results in minor stroke and heart problems. There will be certain changes in the brain when the cerebrovascular disease develops in the body and leads to strokes and lesions and resulting alternations in cognition.
Session 4: Frontotemporal Dementia
Frontotemporal Dementia is a broad term used to describe a group of illnesses characterized by progressive nerve cell loss in the frontal and temporal lobes of the brain. Patients with Frontotemporal Dementia lose 70% of their spindle neurons, while other neurons remain unaffected. Frontotemporal Dementia includes changes in behaviour, personality and speech problems. In younger adults, it is a major cause of dementia. Frontal and temporal lobe atrophy may be visible on MRI scans.
Session 5: Semantic Dementia
Semantic dementia is characterized by a gradual loss of the ability to remember the meaning of words, faces, and things as a result of brain shrinkage in the temporal lobes. Over the course of a year, some people exhibit little change, while others change faster. Usually, tracking a person's growth over a year will provide a good indication of how fast they will progress in the future.
Session 6: Alzheimer’s disease
Alzheimer's disease is the start of moderate memory loss caused by a loss of capacity to do essential tasks. Alzheimer's disease is a progressive, irreversible brain illness that impairs remembering, wondering, and the ability to execute even the most basic tasks. Family history is the most common risk factor.
Session 7: Dementia Nursing
Currently, there is no cure for dementia; the focus of the treatment is to slow the progression of dementia and empower people with dementia to live well. To keep their uniqueness, a person with dementia may brawl. As a result, caregivers must encourage the person with dementia to focus on their goals rather than on what they can no longer accomplish.
Session 8: Dementia Care Management
Dementia care management has been offered at the homes of dementia patients for six months. It is a model of coordinated care that is also defined as a complicated intervention aimed at providing patients with the best possible treatment and care. Dementia care management has been targeted to the needs of each individual patient and is overseen by six dementia-trained study nurses.
Session 9: Causes & risk factors for Dementia
Dementia is a degenerative disease; one of the most important risk factors for Dementia is age; people over the age of 65 are more likely to get Dementia. Although age and genetic inheritance from ancestors are uncontrollable, additional risk factors such as hypertension, hyperlipidemia, hyperthyroidism, excessive alcohol consumption, and smoking can be avoided or managed. Dementia can be caused by a head injury, a stroke, or a brain tumour. A healthy lifestyle and correct food can help to prevent a number of risk factors.
Session 10: Dementia Diagnosis
The Mini-Mental State Examination (MMSE), the Mental Score Test, and the Trail Making Test are all tests that can be used to detect dementia. In Vascular Dementia, MRI and CT scans of the brain are used to look for brain tumours and strokes. According to neurology congresses, a dementia diagnosis is frequently deceptive of many conditions such as Parkinson's disease. As a result, the Dementia Society is on the hunt for innovative research procedures and approaches in order to produce more accurate diagnostic tools.
Session 11: Treatment of Dementia
Dementia treatment is determined by the underlying cause. There is no cure for neurodegenerative dementias like Alzheimer's, but there are drugs that can help protect the brain or control symptoms like anxiety and behavioural problems. Many therapeutic alternatives are being developed as a result of research. A healthy lifestyle, which includes nutritious food, regular exercise, and maintaining social contacts, may minimize the number of persons suffering from dementia and lowers the risk of chronic disease.
Session 12: Bioinformatics approach for Dementia
The advent of bioinformatics can be used to manage and analyze data generated by today's high-throughput research tools, paving the way for new discoveries in the field of dementia. Epigenomes have been found to have relatively little published data. The data is believed to have come from high-throughput technologies used in human brain screening.
Session 13: Advance Drug for Dementia
There are just a few drugs available to treat dementia, such as cholinesterase inhibitors (Memantine, Galantamine) and n-choline receptor agonists, which are used to treat Alzheimer's disease, dementia, Vascular dementia, as well as Parkinson's disease. Additionally, these medicines will improve cognition. This also includes neuroprotective medications like nimodipine, propentofylline, and posatirelin, which are currently being researched and may be effective in the treatment of Dementia.
Session 14: Dementia Awareness
It is critical to raise awareness among dementia-affected families and the general public in order to have a better understanding of how dementia is viewed. If the amount and depth of public awareness of dementia are not fully recognized, then communication with people to help, educate, and clarify misconceptions will be unsuccessful.
In the period 2021 to 2028, the Dementia market is expected to increase. The global dementia disease market has been divided into five major regions: Europe (the U.K, Germany, Italy, Spain, France, and the Rest of Europe) North America (the U.S. and Canada), Asia Pacific (Japan, India, Australia, China & New Zealand, and Rest of Asia Pacific), Latin America (Mexico, Brazil, and Rest of Latin America), and Middle East & Africa (South GCC Countries, Africa, and Rest of the Middle East & Africa).
In 2014, an estimated 5.0 million persons over the age of 65 had dementia, with the number expected to rise to over 14 million by 2060.